About Salspera
Bringing hope to patients with terminal solid tumors
Salspera is a privately held and privately funded, small biopharma company focused on terminal solid tumor cancers.
Our mission
Salspera's lead program, Saltikva®, provides patients and oncologists with a novel immunotherapeutic option for some of the most difficult-to-treat cancers. Our singular mission is to bring this promising therapeutic — and other pipeline candidates — to the patients who need them most.
We work with expert, professional consultants and advisors across the areas essential to advancing a new therapy, including clinical trial monitoring, regulatory affairs, and trial design.
Privately held & privately funded biopharma · Focused on terminal solid tumor cancers · Lead program: Saltikva®, a microbial immunotherapy · Pipeline of additional immuno-modulating constructs in development.
Leadership
Guided by scientific and clinical expertise
Eddie Moradian
Leads Salspera's strategy and operations. Educated at the Swiss Federal Institute of Technology in Zurich (ETH Zürich).
Daniel Saltzman
Originator of the technology platform behind Saltikva®. Holds credentials from the University of Minnesota and brings deep expertise in surgical oncology and microbial immunotherapy.
Want to learn more about our work?
Reach out to our team to discuss Salspera, Saltikva®, and our developing pipeline.
Contact us